Athira Pharma Inc.’s filing revealed that its See Below Gengos Andrew acquired Company’s shares for reported $51445.0 on Jun 07. In the deal valued at $3.43 per share,15,000 shares were bought. As a result of this transaction, Gengos Andrew now holds 80,012 shares worth roughly $ 0.18 million.
Then, Gengos Andrew bought 45,000 shares, generating $135,150 in total proceeds. Upon buying the shares at $3.00, the See Below now owns 65,012 shares.
Before that, Gengos Andrew bought 20,012 shares. Athira Pharma Inc. shares valued at $56,422 were divested by the See Below at a price of $2.82 per share. As a result of the transaction, Gengos Andrew now holds 20,012 shares, worth roughly $45427.24.
JMP Securities upgraded its Athira Pharma Inc. [ATHA] rating to a Mkt outperform from a a Mkt perform in a research note published on Friday. PT values the company’s stock at a premium of 88.65 to its Friday closing price.
Price Performance Review of ATHA
On Friday, Athira Pharma Inc. [NASDAQ:ATHA] saw its stock jump 1.79% to $2.27. On the same session, the stock had its day’s lowest price of $2.24, but rose to a high of $2.31. Over the last five days, the stock has lost -2.58%. Athira Pharma Inc. shares have fallen nearly -28.39% since the year began. Nevertheless, the stocks have fallen -32.84% over the past one year. While a 52-week high of $4.41 was reached on 02/01/23, a 52-week low of $2.21 was recorded on 08/28/23. SMA at 50 days reached $2.81, while 200 days put it at $2.99. A total of 0.12 million shares were traded, compared to the trading of 0.16 million shares in the previous session.
Levels Of Support And Resistance For ATHA Stock
The 24-hour chart illustrates a support level at 2.24, which if violated will result in even more drops to 2.20. On the upside, there is a resistance level at 2.31. A further resistance level may holdings at 2.34. The Relative Strength Index (RSI) on the 14-day chart is 30.54, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.20, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.55%. Stochastics %K at 7.00% indicates the stock is a buying.
How much short interest is there in Athira Pharma Inc.?
A steep rise in short interest was recorded in Athira Pharma Inc. stocks on Aug 14, 2023, dropping by -0.23 million shares to a total of 1.0 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 1.23 million shares. There was a decline of -23.5%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 3.58% of the overall stock float, the days-to-cover ratio (short ratio) fell to 5.25.
Athira Pharma Inc. [ATHA] – Who Are The Largest Shareholders?
In filings from Perceptive Advisors LLC, it is revealed that the company now owns 4,797,278 shares, or roughly 12.64% of the outstanding ATHA shares. Additionally, Baker Bros. Advisors LP increased 34.18% of its stake after which the total value it holdings stand at $9,209,116. Over the last quarter, The Vanguard Group, Inc. sold -126,744 shares of Athira Pharma Inc., while Simplify Asset Management, Inc. sold 102,644 shares. At present, Point72 Asset Management LP is holding 905,668 shares valued at $2.64 million. Millennium Management LLC owned 804,424 shares of the company at the time of its most recent 13F filing, worth $2.35 million.
According to FactSet, Athira Pharma Inc.’s share price will average $8.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 124.22 percent from its previous closing price of $2.23. Analysts expect Athira Pharma Inc. stock to reach the higher price of $19.00, while the lowest price estimate is $3.00. However, 5 analysts have rated ATHA stock as an Overweight in their predictions for 2023.